Amato, Ottavia http://orcid.org/0000-0002-3690-8542
Giannopoulou, Nefeli
Ignatiadis, Michail http://orcid.org/0000-0002-4493-3748
Funding for this research was provided by:
L'Association Jules Bordet
Article History
Received: 3 December 2023
Accepted: 22 February 2024
First Online: 12 March 2024
Competing interests
: O.A. and N.G. declare no competing financial or non-financial interests. M.I. declares the following competing financial interests: Consultant for: Seattle Genetics, Rejuveron senescence therapeutics, Gilead Sciences, Menarini/Stemline, Daichi; Speaker’s Bureau for: Novartis; Grant/Research support from: Roche (my institution), Inivata Inc (my institution), Natera Inc (my institution), Pfizer (my institution). M.I. is Chair of the EORTC Breast Cancer Group.